FirstScan Composition Analysis
(real time tissue characterization)

Spectros is anticipating FDA approval for a tissue composition monitor based on broadband NIRS. Much like the innovative VLS T-Stat which uses many wavelengths of light in the visible, the FirstScan NIRS device uses a large number of wavelengths only this time in the infrared. This device is also available on a research basis for animal and cell research on request.

Breast *

In the breast, tissue composition can map the presence of fat, water, and tissue. Large collections of water represent cysts, while deoxygenated tissues in the middle of fat-filled regions may be abnormal ductal tissues.

Brain *

Standard two-wavelength oximetry is inaccurate, in part due to the presence of fluid shifts and edema. Multiwavelength approaches help solve this issue.

Abdomen *

Standard two-wavelength oximetry is inaccurate, in part due to the presence of bile and stool. Multi-wavelength approaches help solve this issue.

     * NOTE: These devices are under evaluation and have not been approved by the US FDA for human use. Therefore, they are authorized for ex vivo cell or in vivo animal use only. Human use of these agents is permitted only for investigational use under IRB-approved protocols approved by Spectros.